Principal Investigators at Harbour Cancer & Wellness
Trial investigators at Harbour Clinical Trials are expert medical professionals dedicated to advancing healthcare through high-quality clinical research. They lead each study with precision and care, ensuring safety, ethics, and regulatory compliance. By partnering with innovative sponsors and pharmaceutical companies, they help bring cutting-edge treatments to life, turning scientific breakthroughs into real-world solutions.
Dr Gareth Rivalland
Medical Oncologist working at both Auckland Hospital and Harbour Clinical Trials. Gareth undertook specialist training in Auckland, then a research fellowship in Melbourne, Australia, before returning to New Zealand in 2017.
Gareth completed a Doctorate in Medical Science at the University of Melbourne, studying the immune microenvironment in small cell lung cancer. He has a strong interest in clinical trials and basic research, having been a Principal Investigator of multiple phase 1, 2 and 3 trials.
Gareth's research has been internationally recognised with an American Society of Clinical Oncology Merit Awards (2017). He has numerous research publications in high impact journals such as Lancet Oncology, Journal of Thoracic Oncology, Melanoma Research, and Journal of Surgical Oncology.
Key sub-specialities
- Melanoma/cutaneous malignancies
- Lung cancer
- CO45042 : A Phase III, Randomised, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (PI)
- BG-60366-101 : Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). (PI)
- KeyVibe-010: A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (PI). Second top global recruiter.
- Trials of V940, an investigational personalized mRNA cancer vaccine in melanoma (V940-001; V940-012), NSCLC (V940-002) and advanced cutaneous squamous cell carcinoma (V940-007). (PI)
Dr Sanjeev Deva
Medical Oncologist working at both Auckland Hospital and Harbour Clinical Trials. Sanjeev completed a clinical fellowship in experimental oncology at Guy’s and St. Thomas’ Hospital in London, before returning to Auckland in 2015. Sanjeev established the Auckland Cancer Trials Centre (ACTC) at Auckland Hospital - an early phase trial centre - and is currently the facility’s medical director. He splits his time between ACTC and Harbour Clinical Trials.
Key sub-speciality
- Gastrointestinal cancer
- MK1022-011: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers (PI)
- BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (sub-I)
Other experience
- GO-42144: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (PI)
- BREAKWATER: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (PI)
- BGB-53038 : A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification (PI)
Dr Angela Mweempwa
Medical Oncologist working at both Auckland Hospital and Harbour Clinical Trials. After completing specialist training in Hamilton and Auckland, she undertook a clinical fellowship at Auckland Cancer Trials Centre.
Angela then expanded her expertise with a fellowship in Early Drug Development and Clinical Research at the Peter MacCallum Cancer Centre in Melbourne, Australia, where she also gained valuable experience in neuro-oncology at Royal Melbourne Hospital. This training equipped her to excel as an investigator in early-phase trials, enhancing her clinical research and cancer treatment skills. Since returning to New Zealand, Angela has continued to pursue her interest in clinical trials, serving as principal investigator on early phase studies.
Key sub-specialities
- Gastrointestinal cancer
- Primary brain tumours
- Cancer of the prostate
- BGB-A317-26808-101: A Study Investigating BGB- 26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors (PI)
- BGB-43395 : Alone or as Part of Combination Therapies for Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (PI)
- MK1022-011 : Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (sub-I)
- KeyVibe-010 : A Study of Adjuvant Pembrolizumab/ Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (sub-I)
- Trials of V940, an investigational personalized mRNA cancer vaccine in melanoma (V940-001; V940- 012), NSCLC (V940-002) and advanced cutaneous squamous cell carcinoma (V940-007) (sub-I)
Dr Soizick Mesnage
Medical Oncologist working at both Auckland Hospital and Harbour Clinical Trials. Soizick holds a Master of Science with First Class Honours and became a fellow of the Royal Australasian College of Physicians in 2016. She undertook a clinical research fellowship in oncology at the Gustave Roussy Institute, France. She also holds a clinical diploma in palliative care.
Soizick is Medical Oncology SMO at Auckland City Hospital. Her work on genomic and immune profiles in gynaecological cancers was recognised by the American Society of Clinical Onocology.
Key sub-specialities
- Breast cancer
- Melanoma/skin cancers
- TroFuse 11: Phase 3 Open-label Randomized Controlled Study Of sac-TMT (MK2870) And sac-TMT (MK2870) Plus Pembrolizumab Vs TPC in 1L mTNBC Tumors Expressing PD-L1 At The Cut Off of CPS<10 (PI)
- BGB-43395 : Alone or as Part of Combination Therapies for Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (sub-I)
- KeyVibe-010 : A Study of Adjuvant Pembrolizumab/ Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (sub-I)
- V940-001: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (sub-I)
Other experience
- BO41843 : A Study Evaluating the Effi cacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (PI)
- CAMBRIA-2 : An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (sub-I)
- ASTEFANIA: a Phase III study of ado-trastuzumab emtansine plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy (sub-I)
